Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 8/20 | 1.00 |
| ▸ | MMP2 | P08253 | 6/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | HPGD | P15428 | 3/20 | 0.67 |
| ▸ | RAB9A | P51151 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | MMP14 | P50281 | 4/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8204370 | 0.91 | MMP13 (0.83) | MMP13MMP2KDM4EALDH1A1HPGD | |
| SCHEMBL8209912 | 0.91 | MMP13 (0.83) | MMP13MMP2KDM4EALDH1A1HPGD | |
| SCHEMBL28687276 | 0.90 | MMP13 (0.81) | MMP13MMP2KDM4EALDH1A1HPGD | |
| SCHEMBL8209921 | 0.90 | MMP13 (0.81) | MMP13MMP2KDM4EALDH1A1HPGD | |
| SCHEMBL6517285 | 0.88 | MMP13 (0.79) | MMP13MMP2KDM4EALDH1A1HPGD | |
| SCHEMBL6001724 | 0.86 | MMP13 (0.76) | MMP13MMP2KDM4EALDH1A1HPGD | |
| SCHEMBL12501317 | 0.86 | MMP13 (0.76) | MMP13MMP2KDM4EALDH1A1HPGD | |
| SCHEMBL6514064 | 0.86 | MMP13 (0.76) | MMP13MMP2KDM4EALDH1A1HPGD | |
| SCHEMBL8204629 | 0.86 | MMP13 (0.76) | MMP13MMP2KDM4EALDH1A1HPGD | |
| SCHEMBL24601450 | 0.84 | MMP13 (0.72) | MMP13MMP2KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104860866-B | 5- (substitution carbon acylamino) -1H- indoles -2- carbohydrazide derivatives and its preparation method and application | 厦门大学 | 2018-07-17 | — | — | CN | disclosed |
| US-20050026987-A1 | CBI analogues of the duocarmycins and CC-1065 | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-02-03 | — | — | US | disclosed |
| WO-2004101767-A2 | CBI ANALOGUES OF THE DUOCARMYCINS AND CC-1065 | THE SCRIPPS RESEARCH INSTITUTE (US) | 2004-11-25 | — | — | WO | disclosed |
| CN-1165303-C | DNA-binding indole derivatives, prodrugs and immunoconjugates thereof as antitumor agents | 全景研究有限公司 | 2004-09-08 | — | — | CN | disclosed |
| EP-0918752-A4 | DNA-BINDING INDOLE DERIVATIVES, THEIR PRODRUGS AND IMMUNOCONJUGATES AS ANTICANCER AGENTS | PANORAMA RES INC (US) | 2001-11-21 | — | — | EP | disclosed |
| CN-1219841-A | DNA-binding indole derivatives, their prodrugs and immunoconjugates as anticancer agents | PANORAMA RES INC (US) | 1999-06-16 | — | — | CN | disclosed |
| EP-0918752-A2 | DNA-BINDING INDOLE DERIVATIVES, THEIR PRODRUGS AND IMMUNOCONJUGATES AS ANTICANCER AGENTS | PANORAMA RESEARCH, INC. (US) | 1999-06-02 | — | — | EP | disclosed |
| US-5843937-A | DNA-binding indole derivatives, their prodrugs and immunoconjugates as anticancer agents | PANORAMA RESEARCH, INC. (US) | 1998-12-01 | — | — | US | disclosed |
| WO-1997044000-A2 | DNA-BINDING INDOLE DERIVATIVES, THEIR PRODRUGS AND IMMUNOCONJUGATES AS ANTICANCER AGENTS | PANORAMA RESEARCH, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026987-A1 | CBI analogues of the duocarmycins and CC-1065 | CCNI, SP1, DCK | MMP13 1315/4885MMP2 1486/4885KDM4E 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.